2026-09-01T22:57:21-05:00 2025-10-31 475284605 ERIC ZHANG & ASSOCIATES LLP 860 HILLVIEW CT STE 230 MILPITAS CA 95035 990PF 2024-11-01 464261053 THE JADE AND HOPE FOUNDATION JADE 4082672890 1788 ROSSWOOD DRIVE SAN JOSE CA 95124 KANGLIE CHIANG CEO 4082672890 2026-09-01 1 0 ERIC ZHANG CPA P00548506 4084358828 2024 X 1033607 X X 3 3 3 7548 7548 7548 72347 432896 72347 9810 79898 79898 17361 0 0 0 0 1470 0 0 1470 305 305 0 0 412 387 0 25 2187 692 0 1495 18000 18000 20187 692 0 19495 59711 79206 17361 1523 1297 1297 448493 533150 1032310 450016 534447 1033607 0 0 X 219638 219638 0 0 230378 314809 450016 534447 450016 534447 450016 59711 24720 534447 0 534447 285 SHARES GEV P 2020-01-28 2025-01-09 100599 13412 87187 87187 421.3829 SHARES CITIGROUP P 2021-11-26 2025-02-07 33761 27992 5769 5769 3121 SHARES VALE P 2025-01-30 2025-02-10 29963 31144 -1181 -1181 10212 SHARES VALE P 2024-07-26 2025-02-10 97836 86832 11004 11004 1569 SHARES INTEL P 2025-02-10 2025-03-19 40832 29976 10856 10856 100 SHARES INTEL P 2024-10-01 2025-03-19 2601 2286 315 315 63 SHARES GE P 2021-04-27 2025-05-22 14888 3962 10926 10926 CBIO SPLIT SHARES CASH IN LIEU P 2025-06-17 2025-06-17 5 196 -191 -191 12 SHARES GE P 2020-01-28 2025-07-10 2990 704 2286 2286 1 SHARE LMT P 2025-02-19 2025-08-18 438 427 11 11 4460.8664 SHARES INTC P 2020-12-07 2025-09-10 108983 163618 -54635 -54635 72347 9810 1101 0 1101 0 1101 194 0 0 0 194 4 911 0 0 0 0 0 0 0 0 0 0 1 1 CA 1 1 0 0 0 1 N/A KANGLIE CHIANG 4082672890 1788 ROSSWOOD DRIVE SAN JOSE CA 95124 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 KANGLIE CHIANG 1788 ROSSWOOD DRIVE SAN JOSE CA 95124 CEO 2.00 0 0 0 GRACE CHINGWEI CHIANG 1788 ROSSWOOD DRIVE SAN JOSE CA 95124 SECRETARY 2.00 0 0 0 KATHY CHINGCHI CHIANG 1788 ROSSWOOD DRIVE SAN JOSE CA 95124 CFO 2.00 0 0 0 NONE 0 NONE 0 SEE STATEMENT 0 0 721166 5546 0 726712 0 0 726712 10901 715811 35791 X 19495 0 19495 X 17361 8495 7770 8273 41899 14757 7221 6605 7032 35614 19495 16411 13365 13383 62654 18000 15000 12000 12000 57000 1495 1411 1365 1383 5654 0 0 23861 18446 15199 15471 72977 0 0 0 0 KANGLIE CHIANG GRACE CHINGWEI CHIANG KATHY CHINGCHI CHIANG X CANCER CAREPOINT INC 2505 SAMARITAN DRIVE BUILDING 400 SUITE 402 SAN JOSE CA 95124 N/A PUBLIC CHARITY DONATION 5000 PANCREATIC CANCER ACTION NETWORK INC 1500 ROSECRANS AVE STE 200 MANHATTAN BEACH CA 90266 N/A PUBLIC CHARITY DONATION 3000 UCSF FOUNDATION UNIVERSITY OF CALIFORNIA SAN FRANCISCO CA 94143 N/A PUBLIC CHARITY DONATION 10000 18000 0 14 3 14 7548 18 72347 0 79898 0 79898 0 0 0 0 0 0 0 0 0 0 TAX PREPARATION FEE 1470 0 0 1470 SUMMARY OF DIRECT CHARITABLE ACTIVITIES FORM 990PF/PART VIII-A THE JADE AND HOPE FOUNDATION2025 ANNUAL STATEMENTIN 2025, THE JADE AND HOPE FOUNDATION GAVE A COMBINED $18,000 TO THREE ORGANIZATIONS AT THE FOREFRONT OF PANCREATIC CANCER RESEARCH, TREATMENT, AND PATIENT SUPPORT: UCSF'S HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER, THE PANCREATIC CANCER ACTION NETWORK (PANCAN), AND CANCER CAREPOINT. EACH GIFT HELP ADVANCING THE CAUSES CLOSEST TO OUR MISSION IMPROVING THE QUALITY OF LIFE AND EXPANDING TREATMENT OPTIONS FOR THOSE BATTLING PANCREATIC CANCER, AND SUPPORTING PATIENTS AND FAMILIES THROUGH THEIR JOURNEY.UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTERON AUGUST 11, 2025, THE FOUNDATION MADE A $10,000 GIFT TO UCSF'S PANCREAS CENTER FUND. IN A LETTER DATED SEPTEMBER 18, 2025, DR. MARGARET A. TEMPERO, DIRECTOR OF THE UCSF PANCREAS CENTER, THANKED THE FOUNDATION AND SHARED THE CENTER'S PROGRESS OVER THE PAST YEAR. PANCREAS CENTER MEMBERS PUBLISHED MORE THAN TWENTY JOURNAL ARTICLES ADVANCING THE UNDERSTANDING OF PANCREATIC CANCER AND POINTING TOWARD PROMISING NEW THERAPIES: DR. RUSHIKA PERERA'S TEAM UNCOVERED HOW PANCREATIC CANCER CELLS METASTASIZE; DR. DAVIDE RUGGERO'S GROUP INCLUDING LEAD AUTHOR AND PANCREAS CENTER MENTORED SCIENTIST AWARD RECIPIENT DR. JOANNA KOVALSKI IDENTIFIED A WAY TO BLOCK A KEY PROTEIN THAT DRIVES CANCER GROWTH; DR. JIM WELLS AND COLLEAGUES SHOWED HOW THE LOW-OXYGEN ENVIRONMENT TYPICAL OF PANCREATIC TUMORS RESHAPES PROTEINS ON CANCER CELL SURFACES, REVEALING POTENTIAL NEW DRUG TARGETS; AND DR. NADAV AHITUV'S GROUP USED CRISPR TO REPROGRAM FAT CELLS INTO NUTRIENT-STARVING "BEIGE FAT CELLS," DRAMATICALLY SHRINKING TUMORS IN EARLY STUDIES.UCSF ALSO REMAINS A LEADING SITE IN A PHASE III TRIAL TESTING AN ORAL DRUG THAT BLOCKS SIGNALING THROUGH MUTATED RAS PRESENT IN 90% OF PANCREATIC CANCERS WITH EARLY RESULTS DESCRIBED AS HIGHLY ENCOURAGING. UNDER DR. ANDREW KO, CHIEF MEDICAL OFFICER FOR THE PANCREAS CENTER, OTHER ACTIVE TRIALS INCLUDE NATIONWIDE STUDIES OPTIMIZING CHEMOTHERAPY FOR BRCA- AND PALB2-ASSOCIATED PANCREATIC CANCER, A NOVEL MAINTENANCE STRATEGY FOR METASTATIC DISEASE, A PERSONALIZED MRNA VACCINE ADMINISTERED AFTER SURGERY, AND COMBINATION STUDIES PAIRING CHEMOTHERAPY WITH NEW IMMUNOTHERAPY AND TARGETED AGENTS. EARLIER IN THE YEAR, UCSF HOSTED THE UC PANCREATIC CANCER CONSORTIUM'S ANNUAL SYMPOSIUM, BRINGING TOGETHER FACULTY AND TRAINEES FROM ALL FIVE UC CANCER CENTERS, WITH A KEYNOTE ADDRESS FROM DR. KEVAN SHOKAT, WHOSE RESEARCH HAS LED TO MULTIPLE NEW PANCREATIC CANCER DRUGS NOW IN CLINICAL TESTING. THIS WORK BUILDS ON A LANDMARK YEAR FOR UCSF'S BROADER CANCER PROGRAM, WHICH ALSO LAUNCHED THE $200 MILLION WEILL CANCER HUB WEST INITIATIVE WITH STANFORD AND BROKE GROUND ON A NEW ADVANCED CANCER CENTER IN SAN FRANCISCO'S DOGPATCH NEIGHBORHOOD.PANCREATIC CANCER ACTION NETWORK (PANCAN)ON AUGUST 12, 2025, THE FOUNDATION CONTRIBUTED $3,000 TO PANCAN. 2025 WAS A PIVOTAL YEAR FOR PANCREATIC CANCER RESEARCH: PANCAN'S PRECISION PROMISE ADAPTIVE CLINICAL TRIAL PLATFORM, WHICH THE FOUNDATION HAS LONG SUPPORTED, CONTINUED TO GENERATE INSIGHTS, WHILE THE RASOLUTE 302 PHASE 3 TRIAL COMPLETED ENROLLMENT TESTING DARAXONRASIB, A DRUG THAT TARGETS RAS MUTATIONS PRESENT IN MORE THAN 90% OF PANCREATIC CANCERS A MILESTONE SIGNIFICANT ENOUGH THAT THE FDA GRANTED IT A PRIORITY REVIEW VOUCHER. PANCAN'S EARLY DETECTION INITIATIVE SURPASSED 8,800 ENROLLED PARTICIPANTS STUDYING THE LINK BETWEEN NEW-ONSET DIABETES AND PANCREATIC CANCER, AND THE FDA APPROVED A NEW TREATMENT, CABOMETYX (CABOZANTINIB), FOR PANCREATIC NEUROENDOCRINE TUMORS. AMID FEDERAL RESEARCH FUNDING UNCERTAINTY, PANCAN LAUNCHED NEW RESEARCH RECOVERY GRANTS TO PROTECT PROMISING SCIENCE FROM DISRUPTION, AND EXPANDED ITS USE OF AI THROUGH A NEW PARTNERSHIP WITH ACURION APPLYING ITS ONCOGAZE PLATFORM TO PANCAN'S SPARK PATIENT-DATA SYSTEM. PANCAN ALSO LAUNCHED A NEW PARTNERSHIP WITH SMART PATIENTS, GIVING PATIENTS AND CAREGIVERS A REAL-TIME ONLINE COMMUNITY FOR SUPPORT BUILDING ON THE KNOW YOUR TUMOR PRECISION MEDICINE PROGRAM THE FOUNDATION HAS FOLLOWED CLOSELY FOR YEARS.CANCER CAREPOINTON AUGUST 8, 2025, THE FOUNDATION GAVE $5,000 TO CANCER CAREPOINT, EXTENDING OUR LONG-STANDING SUPPORT FOR CANCER PATIENTS AND FAMILIES IN THE SAN JOSE AREA. CANCER CAREPOINT CONTINUES TO PROVIDE PERSONALIZED COUNSELING, NUTRITION EDUCATION, MOVEMENT AND MIND-BODY PROGRAMS, A WIG BANK, AND PEER-LED SUPPORT GROUPS AT NO COST TO BAY AREA CANCER PATIENTS, SURVIVORS, AND CAREGIVERS. THE ORGANIZATION'S MOMENTUM CONTINUED THROUGH 2025: ITS ANNUAL GARDEN PARTY FUNDRAISER AT NESTLDOWN IN LOS GATOS DREW MORE THAN 350 GUESTS AND RAISED OVER $1 MILLION TO SUPPORT FREE PATIENT SERVICES, AND CANCER CAREPOINT WAS FEATURED IN THE SILICON VALLEY BUSINESS JOURNAL, THE MERCURY NEWS WISHBOOK SERIES, AND ON KRON 4 NEWS FOR ITS WORK EXPANDING FREE SUPPORT SERVICES INCLUDING A GROWING URGENT-CARE FUND TO REACH MORE SILICON VALLEY FAMILIES FACING A CANCER DIAGNOSIS.TOGETHER, THESE 2025 GIFTS REFLECT THE JADE AND HOPE FOUNDATION'S CONTINUED, HOLISTIC COMMITMENT TO THE FIGHT AGAINST PANCREATIC CANCER: BACKING UCSF'S CUTTING-EDGE, PERSONALIZED CLINICAL RESEARCH; FUELING PANCAN'S NATIONAL WORK IN PRECISION MEDICINE, EARLY DETECTION, AND PATIENT ADVOCACY; AND SUSTAINING CANCER CAREPOINT'S COMPASSIONATE, NO-COST SUPPORT FOR LOCAL PATIENTS AND FAMILIES. THESE CONTRIBUTIONS REAFFIRM OUR BELIEF THAT RESEARCH, ADVOCACY, AND COMMUNITY CARE MUST ADVANCE TOGETHER TO CHANGE THE COURSE OF THIS DISEASE. INVESTMENT STOCKS FROM CHARLES SCHWAB 533150 1032310 FILLING FEE 25 0 0 25 INVESTMENT EXPENSE 387 387 0 0 PRIOR YEAR ADJUSTMENT 24720 FOREIGN TAX 305 305 0 0